Stellenwert monoklonaler Antikörper und oraler Tyrosinkinase-Inhibitoren in der Therapie des fortgeschrittenen Pankreaskarzinoms

Zusammenfassung

Seit etwa einer Dekade gilt die Gemcitabintherapie als international anerkannte Standardbehandlung des fortgeschrittenen Pankreaskarzinoms. In einer Vielzahl von randomisierten Phase-III-Studien konnte bisher kein eindeutiger Überlebensvorteil für eine Gemcitabin-basierte Kombinationschemotherapie gezeigt werden. Vor diesem Hintergrund und basierend auf viel versprechenden präklinischen Daten verfolgen aktuelle Therapieansätze vor allem die Einbeziehung von molekular-gezielten Substanzen in die Therapieprotokolle beim fortgeschrittenen Pankreaskarzinom. Die vorliegende Arbeit gibt einen Überblick über die aktuellen Studiendaten zu monoklonalen Antikörpern und zu oralen Tyrosinkinase-Inhibitoren und zudem auch einen Ausblick über künftige Konzepte der molekularen Patientenselektion beim inoperablen Pankreaskarzinom.

Summary

Since more than 10 years, single-agent gemcitabine is regarded as an international standard of care for patients with advanced pancreatic cancer. So far, several randomized phase III trials failed to show a significant survival benefit for a gemcitabine-based combination chemotherapy regimen. Based on these negative chemotherapy trials and on promising preclinical data, current treatment concepts in advanced pancreatic cancer include the introduction of molecular targeted agents in clinical trials. This review summarizes the currently available data from clinical trials with monoclonal antibodies and oral tyrosine kinase inhibitors and also gives a perspective for molecular-based patient selection concepts in non-resectable pancreatic cancer.

Schlüsselwörter

Antikörper - Chemotherapie - Gemcitabin - Pankreaskarzinom - Tyrosinkinase-Inhibitor

Keywords

Antibody - Chemotherapy - Gemcitabine - Pancreatic Cancer - Tyrosine Kinase Inhibitor

Literatur

• 01 Adler G. et al. . S3 guidelines „exocrine pancreatic cancer”.  Z Gastroenterol. 2007;  45 487-523
• 02 Amado R G. et al. . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1626-1635
• 03 Burris H A. et al. . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial.  J Clin Oncol. 1997;  15 2403-2413
• 04 Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.  Oncologist. 2008;  13 289-298
• 05 Burtness B A. et al. . Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r).  Proc Am Soc Clin Oncol. 2007;  25
• 06 Cascinu S. et al. . Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicenter, phase II trial.  Lancet Oncol. 2008;  9 39-44
• 07 Danese M D. et al. . Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.  Clin Ther. 2008;  30 775-784
• 08 Duffy A. et al. . A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.  Ann Oncol. 2008;  19 86-91
• 09 Gharibo M. et al. . A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.  Pancreas. 2008;  36 341-345
• 10 Graeven U. et al. . Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD72000) combined with gemcitabine in advanced pancreatic cancer.  Br J Cancer. 2006;  94 1293-1299
• 11 Javle M M. al. . Phase II study of gemcitabine, capecitabine and bevacizumab for advanced pancreatic cancer (APC) with ECOG PS 0-1.  Proc Am Soc Clin Oncol. 2006;  24
• 12 Kim G P. et al. . NCCTG phase II trial of bevacizumab, gemcitabine and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.  Proc Am Soc Clin Oncol. 2006;  24
• 13 Kindler H L. et al. . Final analysis of a randomized phase II trial of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC).  Proc Am Soc Clin Oncol. 2008;  26
• 14 Kindler H L. et al. . Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.  J Clin Oncol. 2005;  23 8033-8040
• 15 Kindler H L. et al. . A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303.  Proc Am Soc Clin Oncol. 2007;  25
• 16 Ko A H. et al. . A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?.  Invest New Drugs. 2008; 
• 17 Lee J. et al. . Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.  Cancer. 2007;  109 1561-1569
• 18 Moore M J. et al. . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.  JCO. 2007;  25 1960-1966
• 19 Moore M J. et al. . The relationship of k-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3.  Proc Am Soc Clin Oncol. 2007;  25
• 20 O'Reilly E M. et al. . A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603.  Proc Am Soc Clin Oncol. 2008;  26
• 21 Philip P A. et al. . Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study.  Proc Am Soc Clin Oncol. 2007;  25
• 22 Safran H. et al. . Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress Her2/neu.  Cancer Invest. 2004;  22 706-712
• 23 Safran H. et al. . Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.  Am J Clin Oncol. 2008;  31 140-144
• 24 Siu L L. et al. . Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.  Clin Cancer Res. 2006;  12 144-151
• 25 Spano J P. et al. . Efficacy of gemcitabine plus axitinib compared to gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.  Lancet. 2008;  371 2101-2108
• 26 Vervenne W. et al. . A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer.  Proc Am Soc Clin Oncol. 2008;  26
• 27 Wallace J A. et al. . Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium.  Proc Am Soc Clin Oncol. 2007;  25
• 28 Xiong H Q. et al. . Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial.  J Clin Oncol. 2004;  22 2610-2616

Korrespondenzadresse